Claims:

1. A fibrinogen-based tissue adhesive, characterized in that it comprises an admixed elastase inhibitor.

2. A tissue adhesive according to claim 1, characterized in that the elastase inhibitor is selected from the group of eglin, elastase-α_1-proteinase inhibitor, α_1-antiprotease, leukocyte protease inhibitor, elafin, or mixtures thereof.

3. A tissue adhesive according to claim 2, characterized in that the leukocyte protease inhibitor is provided as a leukocyte fraction, in particular a granulocyte-derived fraction.

4. A tissue adhesive according to any one of claims 1 to 3, characterized in that it is composed exclusively of human proteins.

5. A tissue adhesive according to any one of claims 1 to 4, characterized in that it is composed exclusively of human blood- or plasma proteins.

6. A tissue adhesive according to any one of claims 1 to 5, characterized in that the elastase inhibitor is contained in an amount ratio of from 1:100 to

1:150,000, preferably 1:500 to 1:110,000, based on mg of fibrinogen.

7. A tissue adhesive according to any one of claims 1 to 6, characterized in that at least 10^{-6} U of elastase inhibitor are contained per g of fibrinogen, preferably between 10^{-3} and 10 U/g of fibrinogen.

8. A tissue adhesive according to any one of claims 1 to 7, characterized in that it contains plasminogen in an amount of at least 0.0001 mg/mg of fibrinogen, preferably at least 0.001, most preferred more than 0.01.

9. A tissue adhesive according to any one of claims 1 to 7, characterized in that it does not contain any plasminogen.

10. A tissue adhesive according to any one of claims 1 to 9, characterized in that it further comprises a plasmin inhibitor or a plasmin activator inhibitor which preferably is selected from the group of aprotinin, α_2-macroglobulin, α_1-antitrypsin, ε-aminocaproic acid, tranexamic acid, or mixtures thereof.

11. A tissue adhesive according to any one of claims

1 to 10, characterized in that it comprises an antibiotic which preferably is selected from the group of aminoglycosides, betalactams, polypeptides, phosphomycin, tetracyclines or mixtures thereof.

12. A tissue adhesive according to any one of claims 1 to 11, characterized in that it comprises factor XIII, preferably in an amount of at least 0.001 U/mg of fibrinogen, particularly preferred at least 0.1 U/mg.

13. A tissue adhesive according to any one of claims 1 to 12, characterized in that it is free from kininogenic proteins.

14. A tissue adhesive according to any one of claims 1 to 13, characterized in that it is present in combination with a solid surface as a fleece.

15. A tissue adhesive according to claim 14, characterized in that the solid surface is a collagen, gelatin or polysaccharide surface.

16. A tissue adhesive according to any one of claims 1 to 15, characterized in that in an environment of high fibrinolytic activity it is resistant to lysis for a period of time of at least 10 hours, preferably at least 15 hours.

17. A tissue adhesive according to any one of claims 1 to 16, characterized in that it is lyophilized.

18. A tissue adhesive according to any one of claims 1 to 16, characterized in that it is present in solution.

19. A tissue adhesive according to claim 18, characterized in that the solution is deep-frozen.

20. A tissue adhesive according to any one of claims 1 to 19, characterized in that it is present in virus-inactivated form.

21. A tissue adhesive according to any one of claims 1 to 20, characterized in that the elastase inhibitor is of recombinant origin.

22. A tissue adhesive system, characterized in that it comprises a tissue adhesive according to any one of claims 1 to 21 as one component thereof.

23. A tissue adhesive system according to claim 22, characterized in that it further comprises a component which comprises thrombin and, optionally, calcium.

24. A tissue adhesive system, characterized in that it comprises a fibrinogen component and a component which comprises an elastase inhibitor.

25. A tissue adhesive system according to claim 24, characterized in that the component which comprises an elastase inhibitor comprises thrombin.

26. A tissue adhesive system according to any one of claims 22 to 25, characterized in that it further comprises an application device for the component(s) of the system, in particular a double-syringe system.

27. The use of a tissue adhesive according to any one of claims 1 to 19 for producing a preparation to be applied in fields with high fibrinolytic activity, in particular in urology.

28. The use of a tissue adhesive sytem according to any one of claims 22 to 26 for producing an application device to be employed in fields with high fibrinolytic activity, in particular in urology.

add a2